Gynecologic Oncology

Gynecologic Oncology

Unless otherwise specified, outcomes reported here reflect care by gynecology staff practicing in Cleveland Clinic facilities in northeast Ohio.

The advent of robotic assisted laparoscopy has prompted an increase in minimally invasive procedures in the gynecologic subspecialties. Cleveland Clinic gynecologic oncology surgeons strive to provide the best care for patients while using minimally invasive procedures when possible.

Surgical Case Approach for Complex Benign and Malignant Cases

2015 – 2018

New Surgical Cancer Case Distribution

2015-2018

Primary Cytoreduction for Ovarian Cancerᵃ

2015 – 2018

ᵃData exclude patients who received chemotherapy prior to primary cytoreduction.

Length of Stay Following Inpatient Gynecologic Oncology Surgeryᵃ

2016 – 2018

ᵃThese data are prepared using the Vizient Clinical Database. Data from the Vizient Clinical Data Base/Resource Manager™ used by permission of Vizient. All rights reserved.

ᵇTotal number of surgical cases for gynecologic malignancy identified by MS-DRGs 734, 735, 736, 737, 738, 739, 740, 741, 754, 755, and 756.

Thirty-Day Readmission Rate Following Inpatient Gynecologic Oncology Surgeryᵃ

2016 – 2018

ᵃThese data are prepared using the Vizient Clinical Database. Data from the Vizient Clinical Data Base/Resource Manager™ used by permission of Vizient. All rights reserved.

ᵇBenchmark derived from review of peer organization members of Vizient for surgical cases for gynecologic malignancy identified by MS-DRGs 734, 735, 736, 737, 738, 739, 740, 741, 754, 755, and 756.

ᶜTotal number of surgical cases for gynecologic malignancy identified by MS-DRGs 734, 735, 736, 737, 738, 739, 740, 741, 754, 755, and 756.

Thirty-Day Mortality Rate Following Inpatient Gynecologic Oncology Surgeryᵃ

2016 – 2018

ᵃThese data are prepared using the Vizient Clinical Database. Data from the Vizient Clinical Data Base/Resource Manager™ used by permission of Vizient. All rights reserved.

ᵇTotal number of surgical cases for gynecologic malignancy identified by MS-DRGs 734, 735, 736, 737, 738, 739, 740, 741, 754, 755, and 756.

Use of Brachytherapy in Patients Treated With Primary Radiation With Curative Intent in any Stage of Cervical Cancerᵃ (N = 280)

2008-2018

ᵃIncludes patients treated at main campus, Cleveland Clinic Family Health Centers, Fairview Hospital and Hillcrest Hospital.

Cleveland Clinic's performance was 89.3% (250 of 280 patients; 95% CI, 85.1%-92.7%) from 2008-2018 for the use of brachytherapy in patients treated with primary radiation with curative intent in any stage of cervical cancer.

Chemotherapy Administered to Cervical Cancer Patients who Received Radiation for Stages IB2-IV Cancer or With Positive Pelvic Nodes, Positive Survical Margin, and/or Positive Parametriumᵃ (N = 307)

2008-2018

ᵃIncludes patients treated at main campus, Cleveland Clinic Family Health Centers, Fairview Hospital and Hillcrest Hospital.

Cleveland Clinic's performance was 92.2% (283 of 307 patients; 95% CI, 88.6%-94.9%) from 2008-2018 for chemotherapy administered to cerivcal cancer patients who received radiaiton for stages IB2-IV cancer or with positive pelvic nodes, positive surgical margin, and/or positive parametrium.

Radiation Therapy Completed Within 60 Days of Initiation of Radiation Among Women Diagnosed With any Stage of Cervical Cancerᵃ (N = 234)

2008-2018

ᵃIncludes patients treated at main campus, Cleveland Clinic Family Health Centers, Fairview Hospital and Hillcrest Hospital.

Cleveland Clinic's performance was 92.3% (216 of 234 patients; 95% CI, 88.1%-95.4%) from 2008-2018 for radiation therapy completed within 60 days of initiation of radiation among women diagnosed with any stage of cervical cancer.

Chemotherapy and/or Radiation Administered to Patients With Stage IIIC or IV Endometrial Cancerᵃ (N = 228)

2008-2018

ᵃIncludes patients treated at main campus, Cleveland Clinic Family Health Centers, Fairview Hospital and Hillcrest Hospital.

Cleveland Clinic's performance was 91.2% (208 of 228 patients; 95% CI, 86.8%-94.6%) from 2008-2018 for chemotherapy and/or radiation administered to patients with stage IIIC or IV endometrial cancer.

Endoscopic, Laparoscopic or Robotic Surgery Performed for all Endometrial Cancer for all Stages Except Stage IVᵃ⁻ᵇ (N = 2271)

2009-2018

ᵃIncludes patients treated at main campus, Cleveland Clinic Family Health Centers, Fairview Hospital and Hillcrest Hospital.

ᵇExcludes sarcoma and lymphoma

Cleveland Clinic's performance was 63.8% (1449 of 2271 patients; 95% CI, 61.8%-65.8%) from 2008-2018 for endoscopic, laparoscopic, or robotic sugery performed for endometrial cancer stages I-IIIC.

Chemotherapy Started Within 42 Days After the Date of Most Definitive Surgery in Stages III-IV Ovarian, Fallopian Tube and Peritoneal Cancers (N = 292)

2007-2017

ᵃIncludes patients treated at main campus, Cleveland Clinic Family Health Centers, Fairview Hospital and Hillcrest Hospital.

Cleveland Clinic's performance was 62% (95% CI, 54.8%-68.7%) from 2007-2011 and 74% (95% CI, 68.1%-79.8%) from 2012-2017 for chemotherapy started within 42 days before or after the date of most definite surgery in stages III-IV ovarian, fallopian tube, or peritoneal cancers.

Salpingo-Oophorectomy With Omentectomy, Debulking, Cytoreductive Surgery, or Pelvic Exenteration in Stages I-IIIC Ovarian Cancerᵃ (N = 555)

2008-2018

ᵃIncludes patients treated at main campus, Cleveland Clinic Family Health Centers, Fairview Hospital and Hillcrest Hospital.

Cleveland Clinic's performance was 90% (499 of 555 patients; 95% CI, 87.1%-92.3%) from 2008-2018 for patients receiving Salping-oophorectomy with omenectomy, debulking; cytoreductive surgery; or pelvic exteneration in stages I-IIIC ovarian cancer.